Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
02 February 2024 - 9:30AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that the
company will host a webcast to review preliminary efficacy and
safety data from its ongoing LUNA Phase 2 study of ixoberogene
soroparvovec (Ixo-vec) for the treatment of wet age-related macular
degeneration (wet AMD) on Thursday, February 8th, 2024 at 8:00am
ET. The webcast will include Szilard Kiss, M.D., Professor of
Ophthalmology at Weill Cornell Medical College and an investigator
in Adverum’s LUNA Phase 2 study. Adverum will further detail these
preliminary results at the 47th Annual Meeting of the Macula
Society. The preliminary LUNA results will include safety and
efficacy data at both the 2E11 and 6E10 dose levels. LUNA was fully
enrolled in August 2023.
Macula Society Meeting Presentation
Information |
|
Title: Ixoberogene soroparvovec (Ixo-vec)
Intravitreal Gene Therapy for Neovascular Age-Related Macular
Degeneration: Preliminary Results from the Phase 2 LUNA Study |
|
Date / Time: Thursday, February 8th, 2024 at
10:56am ET, 7:56 am PT |
|
Session: AMD II Neovascular Trials |
|
Presenter: Arshad M. Khanani, M.D., M.A.,
FASRS, Director of Clinical Research at Sierra Eye Associates,
Clinical Associate Professor at University of Nevada, Reno School
of Medicine |
|
|
The presentation from Macula Society will be available on the
News and Publications section of Adverum’s website shortly after
the presentation.
Conference Call and Webcast InformationAdverum
will host a conference call and webcast on Thursday, February 8th,
2024 at 8:00 am ET to discuss the preliminary safety and efficacy
data from the LUNA Phase 2 study of Ixo-vec. To access the webcast
presentation, please click here.
The on-demand webcast presentation may be accessed under Events
and Presentations in the Investors section of Adverum’s website. A
replay of the webcast will be available on the website following
the presentation.
About Adverum BiotechnologiesAdverum
Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that
aims to establish gene therapy as a new standard of care for highly
prevalent ocular diseases with the aspiration of developing
functional cures to restore vision and prevent blindness.
Leveraging the capabilities of its proprietary intravitreal (IVT)
platform, Adverum is developing durable, single-administration
therapies, designed to be delivered in physicians’ offices, to
eliminate the need for frequent ocular injections to treat these
diseases. Adverum is evaluating its novel gene therapy candidate,
ixoberogene soroparvovec (Ixo-vec, formerly referred to as
ADVM-022), as a one-time, IVT injection for patients with
neovascular or wet age-related macular degeneration. Additionally,
by overcoming the challenges associated with current treatment
paradigms for debilitating ocular diseases, Adverum aspires to
transform the standard of care, preserve vision, and create a
profound societal impact around the globe. For more information,
please visit www.adverum.com.
Forward-looking Statements Statements contained
in this press release regarding events or results that may occur in
the future are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements include but are not limited to statements regarding the
anticipated release of initial preliminary efficacy and safety data
from the LUNA trial. Actual results could differ materially from
those anticipated in such forward-looking statements as a result of
various risks and uncertainties, including risks inherent to,
without limitation: Adverum’s novel technology, which makes it
difficult to predict the timing of commencement and completion of
clinical trials; regulatory uncertainties; enrollment
uncertainties; the results of early clinical trials not always
being predictive of future clinical trials and results; and the
potential for future complications or side effects in connection
with use of Ixo-vec. Additional risks and uncertainties facing
Adverum are set forth under the caption “Risk Factors” and
elsewhere in Adverum’s Securities and Exchange Commission (SEC)
filings and reports, including Adverum’s Quarterly Report on Form
10-Q for the quarter ended September 30, 2023 filed with the SEC on
November 9, 2023. All forward-looking statements contained in this
press release speak only as of the date on which they were made.
Adverum undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
Inquiries: Adverum Investor RelationsEmail:
ir@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Sep 2023 to Sep 2024